Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.

The Use of FSH Receptor Polymorphisms To Improve Pregnancy Rates In In-Vitro Fertilization

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01002885

Enrollment

Registered

2009-10-28

Start date

2009-07-31

Completion date

2013-05-31

Last updated

2013-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Infertility, FSH Receptor Polymorphisms

Brief summary

This study is being done to identify if certain sequences (patterns) of key genes (called polymorphisms) may predict a response to fertility medications. The investigators will also determine if the individual response to fertility medications affects pregnancy rates in in-vitro fertilization.

Detailed description

All IVF patients who meet inclusion criteria and not exclusion criteria will be asked to participate in this study. Upon consent, a blood sample will be obtained in 2 EDTA containing lavender topped tubes before, during or within 3 months after their IVF cycle. Genomic DNA will be extracted and saved for genotyping. The Investigators will collect data on each individual's age, ethnic background, and estradiol levels on the day of hCG administration, total gonadotropin amount, clinical pregnancy rates, basal FSH levels, and occurrence of OHSS. The Investigators will then analyze all samples from all patients for their FSH receptor genotypes. Patients will be compensated $75 via a check within 6-8 weeks of their blood drawn.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

1. 100 women less than 35 years old at time of signing the Informed Consent Form. 2. Day 3 FSH level less than or equal to 10 mIU/ml with an estradiol \< 70 pg/ml 3. Day 3 antral follicle count of greater than 10 follicles total. 4. Couples who have male factor infertility, tubal factor infertility, and unexplained infertility.

Exclusion criteria

patients who have: 1. Endometriosis 2. Polycystic ovarian syndrome

Design outcomes

Primary

Measure	Time frame	Description
The primary outcome measure is to evaluate the frequency of FSH receptor polymorphisms in our population.	3 years	The investigators are looking to quantify how often certain FSH receptor Polymorphisms occur in the population and cetain racial groups. We will be looking at patient's race along with the laboratory results.

Secondary

Measure	Time frame
The secondary outcome is to further clarify the variation in response to FSH due to FSH receptor polymorphisms using the protocols largely used in the United States, including our center.	3 years

Countries

United States

Outcome results